These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3545070)

  • 1. Penetration of cefixime into fibrin clots and in vivo efficacy against Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus.
    Bergeron MG; Turcotte A
    Antimicrob Agents Chemother; 1986 Dec; 30(6):913-6. PubMed ID: 3545070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vitro comparative bactericidal effect of cefotaxime and cefixime in a kinetic model].
    Rolin O; Roche G; Bouanchaud DH
    Presse Med; 1989 Oct; 18(32):1569-71. PubMed ID: 2530534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic interaction between RP 59500 and gram-positive bacteria infecting fibrin clots.
    Turcotte A; Bergeron MG
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2211-5. PubMed ID: 1444302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetic and bactericidal characteristics of oral cefixime.
    Brittain DC; Scully BE; Hirose T; Neu HC
    Clin Pharmacol Ther; 1985 Nov; 38(5):590-4. PubMed ID: 4053491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics.
    Nies BA
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):558-61. PubMed ID: 2504600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antibacterial effect of cefixime in the presence of the type of beta-lactamases produced by Enterobacteriaceae].
    Philippon A; Jarlier V; Legrand P; Fournier G; Nicolas MH; Duval J
    Presse Med; 1989 Oct; 18(32):1560-6. PubMed ID: 2530532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third generation oral cephalosporins: comparative in vitro kinetics.
    Speciale A; Blandino G; Nicoletti G
    J Chemother; 1995 May; 7 Suppl 1():9-12. PubMed ID: 8618112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of the new oral cephalosporin cefixime.
    Counts GW; Baugher LK; Ulness BK; Hamilton DJ
    Eur J Clin Microbiol Infect Dis; 1988 Jun; 7(3):428-31. PubMed ID: 3137053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration.
    Stone JW; Linong G; Andrews JM; Wise R
    J Antimicrob Chemother; 1989 Feb; 23(2):221-8. PubMed ID: 2708180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fundamental and clinical studies on cefixime in pediatrics].
    Iwai N; Shibata M; Mizoguchi F; Nakamura H; Katayama M
    Jpn J Antibiot; 1986 Apr; 39(4):1087-105. PubMed ID: 3761539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
    Lepak AJ; Andes DR
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Alteration of bacteria induced by subinhibitory concentrations of cefixime: consequences on bactericidal activity of human polynuclear neutrophils].
    Labro MT; el Benna J; Jemni A
    Pathol Biol (Paris); 1992 May; 40(5):427-32. PubMed ID: 1495824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
    Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections.
    Jain JG; Housman ST; Nicolau DP
    J Antimicrob Chemother; 2014 Sep; 69(9):2443-7. PubMed ID: 24827890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of cefixime in unweaned calves.
    Ziv G; Lavy E; Glickman A; Winkler M
    J Vet Pharmacol Ther; 1995 Apr; 18(2):94-100. PubMed ID: 7629935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field].
    Toyonaga Y; Hatakeyama K; Yamori K; Sakaguchi N; Nakano K; Yamazaki M; Sugita M; Hori M
    Jpn J Antibiot; 1992 Jan; 45(1):48-73. PubMed ID: 1495196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
    Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential increased survival of staphylococci and limited ultrastructural changes in the core of infected fibrin clots after daptomycin administration.
    Michiels MJ; Bergeron MG
    Antimicrob Agents Chemother; 1996 Jan; 40(1):203-11. PubMed ID: 8787906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime.
    Neu HC
    Pediatr Infect Dis J; 1987 Oct; 6(10):958-62. PubMed ID: 3696836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.